MUFG Americas’s Neurocrine Biosciences NBIX Stock Holding History

MUFG Americas’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8	Closed	-$1K	–	552
2022 Q3	$1K	Buy	+8	New	+$812	﹤0.01%	853
2019 Q2	–	Sell	-1,000	Closed	-$88K	–	854
2019 Q1	$88K	Buy	+1,000	New	+$83.6K	﹤0.01%	443

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MUFG Americas's NBIX Position: Q4 2022 in Review

MUFG Americas sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 8 shares — an estimated $1K sold.

MUFG Americas first reported a position in NBIX in Q1 2019 and held it in 2 quarters. The position peaked at $88K in Q1 2019. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

MUFG Americas reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
MUFG Americas sold 8 Neurocrine Biosciences shares in Q4 2022, an estimated $1K.
MUFG Americas first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 2 quarters.
MUFG Americas's Neurocrine Biosciences position peaked at $88K in Q1 2019.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on MUFG Americas's 13F filing for Q4 2022.